Express Healthcare
Home  »  News  »  SMT through partner signs agreement with Italian Government national purchase entity ‘CONSIP’

SMT through partner signs agreement with Italian Government national purchase entity ‘CONSIP’

0 788
Read Article

To deliver up to 40,000 of its bio degradable polymer coated DES ‘Supraflex’ stents by 2022

Sahajanand Medical Technologies (SMT) has won the first ever national tender for drug eluting stent. The selection was made through an open tender with a rigorous focus on quality in terms of superior technology and clinical trial.

SMT through its partner has signed an agreement with the Italian Government national purchase entity ‘CONSIP’ (Consip spa is a society of Economy & Finance Ministry aimed to manage all the purchase orders for public administrations in Italy) to deliver up to 40,000 of its bio degradable polymer coated DES ‘Supraflex’ stents by 2022.

Eight major medical device companies had qualified to participate and based on the rating for advanced product features and clinical trial data, the committee selected SMT as the winner. Supraflex has come at the top of the merit list in the tender because of its excellent clinical data and robust record of safety and efficacy.

Speaking about the win, Gaurav Goel, Head of Western Europe, SMT said, “The tender win in Italy is the validation of our world class quality standards, best-in-class product performance and the clinical data of SMT DES. This achievement follows the pervious tender wins in regions like Emilia Romagna and Sicily amongst others. SMT has been steadily gaining market share in Europe and is being recognised as a top tier player in the DES market.”

Supraflex family, a cardiac drug eluting stent designed and manufactured in India is not only proved to be at par in safety as compared to Abbott’s Xience* but fared numerically better in efficacy in an investigator initiated multi-centre European randomised controlled study with more than 1400 patients, called ‘TALENT’. The findings of the TALENT trial were published in Lancet, world’s leading medical journal.

Gennaro Broya de Lucia, General Manager, EUKON asserts that,” SMT has grown as a first- tier player in the Italian market in a very short time frame. Our combined efforts are giving good results. We have to consider this win as a shift in interventional cardiology paradigm. Our goal will be to keep investing and working to attract more and more professionals to join hands in SMT’s mission to ‘save millions’.”

The market size for stents in Italy is approximately 250,000 DES, annually. It is one of the technologically advanced markets in the world and is an important territory to strengthen SMT’s presence in Europe.


*Supraflex is a trademark of Sahajanand Medical Technologies Pvt. Ltd. or its affiliates. Specifications are subject to modification, revision and improvement.

*Xience family are trademarks of the Abbott Group of Companies.

*The CE Mark indicates that the product satisfies requirements of EU Directives (EU:The European Union) and all products need to be CE certified to be sold in Europe.

Leave A Reply

Your email address will not be published.

Attend an exclusive webinar to know more about biomarkers in diagnosis & therapy management of heart failure.
Register Now
 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
Are you looking for ICP-MS which can increase productivity and remove time trap from your analysis?
Know More